Сравнение

Histrelin vs. Icatibant

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

220810-26-4

138614-30-9

Молекулярная масса

1323.52 g/mol

1304.52 g/mol

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Histrelin

Continuous GnRH-agonist stimulation downregulates and desensitises the pituitary GnRH receptors — after the initial rise, LH, FSH and the sex hormones fall persistently.

Icatibant

Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Histrelin	Icatibant
Германия	Рецептурный	Рецептурный
США	Рецептурный	Рецептурный

Полные записи

Frequently asked questions

What is the difference between Histrelin and Icatibant?: Histrelin is classified as "Исследования (прочее)", while Icatibant is classified as "Исследования (прочее)". Histrelin: Histrelin is a nonapeptide GnRH agonist delivered as a once-yearly implant. Approved for central precocious puberty in children (Supprelin LA) and advanced prostate cancer (Vantas). Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Histrelin or Icatibant?: The highest available evidence level is "РКИ на людях" for Histrelin and "РКИ на людях" for Icatibant. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Histrelin and Icatibant in Germany and the United States?: Германия: Histrelin — Рецептурный, Icatibant — Рецептурный. США: Histrelin — Рецептурный, Icatibant — Рецептурный. These are factual summaries with source and review date on the individual pages.

Country

Histrelin

Icatibant

Германия

Рецептурный

США

Рецептурный

Frequently asked questions

What is the difference between Histrelin and Icatibant?

Histrelin is classified as "Исследования (прочее)", while Icatibant is classified as "Исследования (прочее)". Histrelin: Histrelin is a nonapeptide GnRH agonist delivered as a once-yearly implant. Approved for central precocious puberty in children (Supprelin LA) and advanced prostate cancer (Vantas). Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Histrelin or Icatibant?

The highest available evidence level is "РКИ на людях" for Histrelin and "РКИ на людях" for Icatibant. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Histrelin and Icatibant in Germany and the United States?

Германия: Histrelin — Рецептурный, Icatibant — Рецептурный. США: Histrelin — Рецептурный, Icatibant — Рецептурный. These are factual summaries with source and review date on the individual pages.